Moxetumomab pasudotox (Lumoxiti)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Mechanism of action

A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38)

Diseases for which it is used

History of changes in FDA indication

  • 9/13/2018: Initial FDA approval for adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA). (Based on Study 1053)

Also known as

  • Generic name: moxetumomab pasudotox-tdfk
  • Code names: CAT-8015, HA22
  • Brand name: Lumoxiti